Quantcast

Latest HUMIRA Stories

2009-09-08 09:11:00

NEW YORK, Sept.

2009-09-08 08:59:00

NEW YORK, Sept.

2009-07-15 06:48:00

ABBOTT PARK, Ill., July 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2009.Diluted earnings per share, excluding specified items, were $0.89, at the high end of Abbott's second-quarter guidance range of $0.87 to $0.89.

2009-06-30 14:16:54

The U.S.

2009-04-30 10:49:00

Newly Approved Simponi is Expected to Achieve Strong Uptake in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., April 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA)...


Word of the Day
aphotic
  • Having no light.
  • Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.
The word 'aphotic' comes from Greek roots meaning 'without' and 'light'.
Related